# blaNDM-1 (New Delhi Metallo-Beta-Lactamase 1): Carbapenem Cleavage Kinetics and Plasmid Dissemination


## Key Takeaways

- The *blaNDM-1* gene encodes a zinc-dependent metallo-β-lactamase (NDM-1) that confers resistance to virtually all β-lactam antibiotics, including carbapenems, by hydrolyzing their β-lactam ring.
- NDM-1 is typically harbored on mobile genetic elements, primarily composite transposons like Tn125, which are frequently integrated into broad-host-range plasmids, facilitating rapid horizontal gene transfer across diverse Gram-negative pathogens.
- The enzyme's active site features a binuclear zinc center essential for catalysis, and its broad substrate specificity is attributed to a flexible active site groove that accommodates bulky antibiotic side chains.
- Emerging NDM variants, such as NDM-5 and NDM-7, possess specific amino acid substitutions (e.g., Met154Leu, Asp130Asn) that enhance catalytic efficiency against carbapenems, leading to higher minimum inhibitory concentrations (MICs).
- Infections caused by NDM-producing bacteria are associated with high mortality rates due to limited therapeutic options, with current strategies relying on combination therapies (e.g., polymyxin + carbapenem) or novel agents like cefiderocol.
- Investigational small-molecule inhibitors, particularly boronic acid derivatives like taniborbactam, are in advanced clinical development to restore carbapenem susceptibility by targeting the NDM-1 active site.

---

## Executive Summary & Key Metadata

The gene **blaNDM-1** encodes the New Delhi Metallo-β-Lactamase 1 (NDM-1), a zinc-dependent class B β-lactamase that hydrolyzes virtually all β-lactam antibiotics, including the carbapenem subclass (imipenem, meropenem, ertapenem), which are often reserved as last-line therapeutic agents against multidrug-resistant Gram-negative pathogens. The emergence and global dissemination of blaNDM-1, typically harbored on promiscuous plasmids, represents a paradigm shift in antimicrobial resistance (AMR) epidemiology, effectively rendering many clinical isolates pan-resistant. This reference manual provides a comprehensive, biophysically grounded analysis of the blaNDM-1 gene, from its genomic context and protein architecture to its catalytic mechanism, clinical mutation spectrum, and pharmacologic targeting strategies.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | blaNDM-1 |
| **UniProt Accession** | C7C422 |
| **Representative PDB ID** | 3SPU |
| **Chromosomal Locus** | Not chromosomal; typically plasmid-borne (e.g., IncA/C, IncFII, IncL/M). Chromosomal integration via transposon (Tn125) has been observed. |
| **Primary Molecular Function** | Zinc-dependent hydrolysis of β-lactam ring; carbapenemase activity (EC 3.5.2.6) |
| **Disease & Pathology Associations** | Multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections; bacteremia, pneumonia, urinary tract infections (UTIs), surgical site infections; high mortality rates in immunocompromised hosts |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Genetic Context and Mobilization

Unlike eukaryotic genes, blaNDM-1 does not possess a fixed chromosomal locus. It is an acquired resistance gene, almost exclusively associated with mobile genetic elements (MGEs). The canonical genetic platform is the composite transposon **Tn125** (also designated Tn125-like), which is frequently embedded within a diversity of broad-host-range plasmids belonging to incompatibility groups IncA/C, IncFII, IncL/M, and IncX3 [<a href="#ref-1">1</a>]. The association of blaNDM-1 with these high-copy-number and conjugative plasmids facilitates its rapid horizontal gene transfer (HGT) across Enterobacterales, *Acinetobacter baumannii*, and *[Pseudomonas aeruginosa](/knowledge/bacteria/gram-negative/pseudomonas-aeruginosa-multidrug-resistance-biofilms)*.

The blaNDM-1 gene is flanked by insertion sequences, most notably ISAba125 upstream and IS3000 downstream, which provide the transposition machinery for its mobilization. The upstream ISAba125 element carries a strong promoter that drives high-level expression of blaNDM-1, a critical feature for phenotypic resistance. The genetic environment is highly plastic; variations in the flanking sequences (e.g., deletion of ISAba125) can alter promoter strength and consequently the minimum inhibitory concentration (MIC) of carbapenems [<a href="#ref-2">2</a>].

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of blaNDM-1 is not a classical bacterial promoter. Instead, transcription initiation is driven by outward-directed promoters located within the inverted repeat (IR) of the upstream ISAba125 element. Two overlapping promoters, P1 and P2, have been characterized:

- **P1**: A strong promoter with a -35 box (TTGACA) and a -10 box (TATAAT) that closely matches the *E. coli* σ70 consensus sequence.
- **P2**: A weaker promoter located upstream of P1, contributing to basal expression levels.

The strength of these promoters is a major determinant of the resistance phenotype. Studies have demonstrated that the presence of the complete ISAba125 element increases blaNDM-1 transcription by approximately 10-fold compared to variants with truncated upstream regions [<a href="#ref-2">2</a>]. This transcriptional control is crucial for clinical resistance, as the level of NDM-1 protein must exceed a threshold to effectively titrate the incoming antibiotic concentration.

### 1.3 Isoforms and Variants

The blaNDM-1 gene does not undergo alternative splicing, as it is a prokaryotic gene. However, a large family of allelic variants exists, designated NDM-1 through NDM-XX (e.g., NDM-5, NDM-7, NDM-9). These variants arise from point mutations that result in single amino acid substitutions. While the term "isoform" is not strictly applicable, these variants represent functionally distinct protein products with altered catalytic efficiencies (kcat/Km) and substrate profiles. For instance, NDM-5 (with substitutions Val88Leu and Met154Leu) and NDM-7 (with substitutions Asp130Asn and Met154Leu) exhibit enhanced hydrolytic activity against carbapenems compared to the wild-type NDM-1 [<a href="#ref-3">3</a>]. The structural basis for these differences is discussed in Section 4.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Maturation

NDM-1 is synthesized as a 269-amino-acid precursor protein. The N-terminus contains a 19-residue signal peptide that directs the protein to the Sec-dependent secretion pathway for translocation into the periplasmic space. Upon translocation, the signal peptide is cleaved, yielding the mature, catalytically active 250-amino-acid enzyme (molecular weight ~27.5 kDa) [<a href="#ref-4">4</a>].

The mature NDM-1 adopts a characteristic **αβ/βα sandwich fold**, a hallmark of the metallo-β-lactamase (MBL) superfamily. This fold consists of a central β-sandwich core composed of two mixed β-sheets, flanked by α-helices on either side. The overall architecture is stabilized by a conserved disulfide bridge between Cys26 and Cys208, which is critical for protein stability and resistance to proteolytic degradation in the periplasm [<a href="#ref-4">4</a>].

### 2.2 The Di-Zinc Catalytic Center

The active site is located at the interface of the two β-sheets and contains a binuclear zinc center. Two zinc ions, designated Zn1 and Zn2, are coordinated by a conserved set of amino acid residues:

- **Zn1 (the "catalytic" zinc)**: Coordinated by His120, His122, and His189 (using mature protein numbering). This site is often referred to as the "histidine site."
- **Zn2 (the "co-catalytic" zinc)**: Coordinated by Asp124, His250, and Cys208. This is the "cysteine site."

A bridging water/hydroxide molecule (W1) connects the two zinc ions and serves as the nucleophile in the hydrolytic reaction. The zinc ions are essential for catalysis; removal of zinc (e.g., by chelators like EDTA) results in complete loss of enzymatic activity [<a href="#ref-5">5</a>].

### 2.3 Substrate Binding and the Active Site Groove

The substrate-binding site is a shallow, broad groove that extends across the surface of the enzyme, accommodating the bulky R1 and R2 side chains of β-lactam antibiotics. Key residues involved in substrate recognition and stabilization include:

- **Lys211**: Forms a salt bridge with the carboxylate group of the β-lactam ring.
- **Asn220**: Participates in hydrogen bonding with the acylamino side chain of substrates.
- **Gln123**: Located near the Zn2 site, involved in stabilizing the intermediate state.

The broad substrate specificity of NDM-1 is attributed to the flexibility of the active site loop (residues 60-66), which can accommodate a wide range of β-lactam structures, including the bulky carbapenem side chains [<a href="#ref-6">6</a>].

### 2.4 Structural Comparison with Other MBLs

NDM-1 shares significant structural homology with other subclass B1 MBLs, such as VIM-2 and IMP-1. However, NDM-1 possesses a unique extended loop (residues 152-158) near the active site that is not present in VIM-2. This loop contributes to the enhanced catalytic efficiency of NDM-1 against carbapenems and its resistance to clinically approved MBL inhibitors like avibactam [<a href="#ref-6">6</a>].

> **[Interactive 3D Protein Visualizer: Load blaNDM-1 (PDB: 3SPU)](/tools/protein-structure-viewer?source=direct&pdbId=3SPU)**
>
> Use the visualizer to explore the di-zinc center, the αβ/βα fold, and the active site groove. Highlight residues His120, His122, His189 (Zn1) and Asp124, His250, Cys208 (Zn2) to visualize the catalytic core.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Catalytic Mechanism of Carbapenem Hydrolysis

The molecular function of NDM-1 is the hydrolysis of the β-lactam ring, a four-membered cyclic amide that is the pharmacophore of all β-lactam antibiotics. The reaction proceeds via a two-step mechanism that does not involve a covalent acyl-enzyme intermediate, distinguishing it from serine β-lactamases (classes A, C, D).

**Step 1: Nucleophilic Attack.** The bridging hydroxide (W1) is activated by the binuclear zinc center. Zn1 polarizes the carbonyl group of the β-lactam ring, increasing its electrophilicity. The hydroxide ion performs a nucleophilic attack on the carbonyl carbon, forming a tetrahedral intermediate.

**Step 2: Ring Cleavage and Proton Transfer.** The tetrahedral intermediate collapses, breaking the C-N bond of the β-lactam ring. A proton is transferred from the Zn2-bound water molecule to the nitrogen atom of the leaving group. The product is an open-ring, inactive form of the antibiotic [<a href="#ref-5">5</a>].

The catalytic efficiency (kcat/Km) of NDM-1 for meropenem is approximately 1.5 × 10^6 M^-1 s^-1, which is among the highest reported for MBLs. This high efficiency ensures that even low concentrations of the enzyme can rapidly inactivate the antibiotic before it reaches its penicillin-binding protein (PBP) targets in the periplasm [<a href="#ref-7">7</a>].

### 3.2 Protein-Protein Interactions and the Periplasmic Environment

Unlike eukaryotic signaling pathways, NDM-1 does not participate in a classical phosphorylation cascade. Its function is entirely dependent on its localization and interaction with the periplasmic environment. However, several protein-protein interactions are critical for its biological activity:

- **Sec Translocon**: The SecYEG complex recognizes the N-terminal signal peptide and translocates the unfolded protein across the inner membrane.
- **Signal Peptidase I (LepB)**: Cleaves the signal peptide, releasing the mature protein into the periplasm.
- **Disulfide Bond Oxidoreductase (DsbA/DsbC)**: Facilitates the formation of the critical Cys26-Cys208 disulfide bond. In the absence of DsbA, NDM-1 misfolds and is rapidly degraded by periplasmic proteases (e.g., DegP) [<a href="#ref-4">4</a>].

### 3.3 Interaction with the Bacterial Envelope Stress Response

The expression of blaNDM-1 and the subsequent accumulation of unfolded or misfolded protein in the periplasm can trigger the **Cpx envelope stress response** and the **σE (RpoE) stress response**. These two-component signaling systems are activated by misfolded periplasmic proteins and lead to the upregulation of periplasmic chaperones and proteases. This regulatory feedback loop is crucial for maintaining the fitness of the bacterial host, as high-level NDM-1 production can otherwise be toxic [<a href="#ref-8">8</a>].

```mermaid
sequenceDiagram
    participant Ribosome
    participant SecYEG
    participant Periplasm
    participant NDM1 as "NDM-1 (Mature)"
    participant BetaLactam as "β-lactam Antibiotic"
    participant PBP as "Penicillin-Binding Protein"
    Ribosome->>SecYEG: Translate blaNDM-1 mRNA (pre-protein)
    SecYEG->>Periplasm: Translocate pre-protein
    Periplasm->>Periplasm: Signal Peptidase (LepB) cleavage
    Periplasm->>Periplasm: DsbA/DsbC oxidation (Cys26-Cys208)
    Periplasm->>NDM1: Fold into active αβ/βα structure
    BetaLactam->>NDM1: Substrate binding (e.g., Meropenem)
    NDM1->>NDM1: Zn2+-mediated hydrolysis of β-lactam ring
    NDM1->>BetaLactam: Release inactive (open-ring) product
    Note over BetaLactam, PBP: Antibiotic inactivated, cannot bind PBP
    Note over PBP: Cell wall synthesis proceeds, bacterial survival
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The NDM Variant Family

The rapid global spread of blaNDM-1 has been accompanied by the emergence of numerous variants. These mutations are not random; they cluster in specific regions of the protein that affect substrate specificity, catalytic efficiency, and protein stability. The most clinically significant variants are listed below.

| **Variant** | **Amino Acid Substitution(s)** | **Structural Location** | **Phenotypic Consequence** |
| :--- | :--- | :--- | :--- |
| **NDM-1** | Wild-type | - | Baseline carbapenemase activity |
| **NDM-4** | Met154Leu | Active site loop (152-158) | Increased hydrolysis of carbapenems and cephalosporins |
| **NDM-5** | Val88Leu, Met154Leu | Loop near Zn2 site; Active site loop | Enhanced activity against meropenem and ertapenem |
| **NDM-7** | Asp130Asn, Met154Leu | Near Zn1 site; Active site loop | Significantly increased kcat/Km for carbapenems |
| **NDM-9** | Glu152Lys | Active site loop | Increased activity against cephalosporins |
| **NDM-16** | Arg264His | C-terminal domain | Reduced stability, but altered substrate profile |

### 4.2 Structural Basis for Enhanced Activity

The **Met154Leu** substitution, found in NDM-4, NDM-5, and NDM-7, is a hotspot mutation. Met154 is located in the flexible loop (residues 152-158) that forms one wall of the active site. Substitution with the smaller, more hydrophobic leucine residue increases the volume of the active site cavity, allowing better accommodation of the bulky R2 side chains of carbapenems. This results in a 2- to 4-fold increase in kcat/Km for meropenem [<a href="#ref-3">3</a>].

The **Asp130Asn** substitution (NDM-7) is located near the Zn1 site. Asp130 forms a hydrogen bond with the Zn1-coordinating residue His122. Substitution with asparagine alters the electrostatic environment of the zinc center, increasing the nucleophilicity of the bridging hydroxide and enhancing the catalytic rate [<a href="#ref-3">3</a>].

### 4.3 Clinical Impact and Differential Diagnosis

Infections caused by NDM-producing bacteria are associated with high mortality rates (30-50%) due to limited treatment options. The presence of specific NDM variants can influence the choice of therapy. For example, strains producing NDM-5 or NDM-7 may exhibit higher MICs to meropenem, requiring higher doses or combination therapy. Differential diagnosis involves phenotypic tests (e.g., Carba NP test, modified carbapenem inactivation method) followed by molecular confirmation via PCR and whole-genome sequencing to identify the specific blaNDM variant [<a href="#ref-9">9</a>].

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Bacterial Pathogenesis and Immune Evasion

blaNDM-1 is not a classical virulence factor; its primary role is antibiotic resistance. However, its presence profoundly impacts host-pathogen interactions. By conferring resistance to carbapenems, NDM-1 allows the bacterium to survive in the host despite intensive antibiotic therapy. This prolonged survival provides the bacterium with an opportunity to express other virulence determinants, such as adhesins, toxins, and iron-acquisition systems, leading to more severe and persistent infections.

### 5.2 Interaction with the Host Immune System

The NDM-1 protein itself is not known to directly interact with host immune components. However, the bacterial surface components (e.g., lipopolysaccharide, LPS) of NDM-producing strains can trigger a strong innate immune response via Toll-like receptor 4 (TLR4). The resulting inflammatory cascade can lead to sepsis and septic shock. The failure of antibiotic therapy due to NDM-1 production exacerbates this inflammatory response, as the bacterial burden remains high [<a href="#ref-10">10</a>].

### 5.3 Co-carriage with Other Resistance Mechanisms

blaNDM-1 is frequently co-located on plasmids with other resistance genes, including those encoding extended-spectrum β-lactamases (ESBLs, e.g., blaCTX-M-15), 16S rRNA methyltransferases (e.g., armA, conferring aminoglycoside resistance), and fluoroquinolone resistance determinants (e.g., qnr). This co-carriage leads to the emergence of pan-resistant "superbugs" that are virtually untreatable with conventional antibiotics [<a href="#ref-1">1</a>].

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 The Challenge of MBL Inhibition

The clinical management of NDM-producing infections is extremely challenging. NDM-1 is resistant to clinically available β-lactamase inhibitors, including clavulanic acid, sulbactam, tazobactam, and the newer diazabicyclooctane inhibitor avibactam. This is because these inhibitors are designed to form covalent adducts with the active-site serine of class A, C, and D β-lactamases, a mechanism that is ineffective against the zinc-dependent MBLs.

### 6.2 Current Treatment Strategies

Current therapeutic options are limited to:

- **Combination Therapy**: The most common regimen is a combination of a polymyxin (e.g., colistin) with a carbapenem (e.g., meropenem), sometimes with the addition of tigecycline or fosfomycin. The rationale is that the carbapenem, although hydrolyzed, may act as a "sacrificial substrate" to saturate NDM-1, allowing the polymyxin to exert its membrane-disrupting effect.
- **Cefiderocol**: A novel siderophore-conjugated cephalosporin that exploits the bacterial iron-uptake system to be actively transported into the periplasm, bypassing the need for porin diffusion. Cefiderocol is stable against NDM-1 hydrolysis and is a promising agent for NDM-producing infections [<a href="#ref-11">11</a>].

### 6.3 Investigational Small-Molecule Inhibitors

Several classes of MBL inhibitors are in preclinical or clinical development:

| **Inhibitor Class** | **Example** | **Mechanism of Action** | **Development Stage** |
| :--- | :--- | :--- | :--- |
| **Zinc Chelators** | EDTA, DPA | Remove Zn2 from the active site, inactivating the enzyme | Preclinical (used as diagnostic tool) |
| **Thiol-containing compounds** | Captopril, Thiolactones | Coordinate with the di-zinc center, blocking substrate access | Preclinical |
| **Boronic acid derivatives** | Taniborbactam (VNRX-5133) | Form a covalent bond with the nucleophilic water, mimicking the tetrahedral intermediate | Phase 3 clinical trials |
| **Cyclic boronate** | QPX7728 | Broad-spectrum inhibitor of both serine and metallo-β-lactamases | Phase 1 clinical trials |

**Taniborbactam** is the most advanced MBL inhibitor in clinical development. It is a boronic acid derivative that binds to the di-zinc center of NDM-1 with high affinity (Ki ~ 10 nM). In combination with cefepime, taniborbactam has demonstrated potent activity against NDM-producing Enterobacterales in clinical trials, restoring susceptibility to cefepime [<a href="#ref-12">12</a>].

### 6.4 Gene Therapy and CRISPR-Based Approaches

Given the plasmid-borne nature of blaNDM-1, CRISPR-Cas technology has been explored as a potential strategy to selectively eliminate the resistance plasmid. Conjugation-based delivery of a CRISPR-Cas9 system targeting a unique sequence on the blaNDM-1-carrying plasmid has been shown to re-sensitize bacteria to carbapenems by causing plasmid loss. This approach is still in the early preclinical stage but represents a novel avenue for combating AMR [<a href="#ref-13">13</a>].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for the blaNDM-1 gene and protein.

| **Database** | **Identifier** | **Link** |
| :--- | :--- | :--- |
| **NCBI Gene** | Not applicable (plasmid-borne) | - |
| **NCBI Nucleotide** | FN396876.1 (plasmid pNDM-HK) | [Link](https://www.ncbi.nlm.nih.gov/nuccore/FN396876.1) |
| **UniProtKB** | C7C422 | [Link](https://www.uniprot.org/uniprotkb/C7C422) |
| **RCSB PDB** | 3SPU | [Link](https://www.rcsb.org/structure/3SPU) |
| **CARD (Comprehensive Antibiotic Resistance Database)** | ARO:3000744 | [Link](https://card.mcmaster.ca/ontology/3000744) |
| **Beta-Lactamase Database (BLDB)** | NDM-1 | [Link](http://www.bldb.eu/) |
| **Gene Ontology (GO)** | GO:0008800 (β-lactamase activity); GO:0016787 (hydrolase activity) | [Link](https://www.ebi.ac.uk/QuickGO/) |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009). Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. *Antimicrobial Agents and Chemotherapy*, 53(12), 5046-5054. [https://doi.org/10.1128/AAC.00774-09](https://doi.org/10.1128/AAC.00774-09)

<a id="ref-2"></a>[2] Poirel, L., Dortet, L., Bernabeu, S., & Nordmann, P. (2011). Genetic features of blaNDM-1-positive Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, 55(11), 5403-5407. [https://doi.org/10.1128/AAC.00585-11](https://doi.org/10.1128/AAC.00585-11)

<a id="ref-3"></a>[3] Cheng, Z., Van Puyvelde, S., & Van Bambeke, F. (2018). Biochemical and structural characterization of NDM-7, a novel New Delhi metallo-β-lactamase variant with enhanced carbapenemase activity. *Journal of Antimicrobial Chemotherapy*, 73(4), 941-948. [https://doi.org/10.1093/jac/dkx514](https://doi.org/10.1093/jac/dkx514)

<a id="ref-4"></a>[4] King, D. T., Worrall, L. J., Gruninger, R., & Strynadka, N. C. (2012). New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition. *Journal of the American Chemical Society*, 134(28), 11362-11365. [https://doi.org/10.1021/ja303579d](https://doi.org/10.1021/ja303579d)

<a id="ref-5"></a>[5] Zhang, H., & Hao, Q. (2011). Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. *The FASEB Journal*, 25(8), 2574-2582. [https://doi.org/10.1096/fj.11-184036](https://doi.org/10.1096/fj.11-184036)

<a id="ref-6"></a>[6] Green, V. L., Verma, A., Owens, R. J., Phillips, S. E., & Carr, S. B. (2011). Structure of New Delhi metallo-β-lactamase 1 (NDM-1). *Acta Crystallographica Section F: Structural Biology and Crystallization Communications*, 67(10), 1160-1164. [https://doi.org/10.1107/S1744309111029654](https://doi.org/10.1107/S1744309111029654)

<a id="ref-7"></a>[7] Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019). β-Lactamases and β-lactamase inhibitors in the 21st century. *Journal of Molecular Biology*, 431(18), 3472-3500. [https://doi.org/10.1016/j.jmb.2019.04.002](https://doi.org/10.1016/j.jmb.2019.04.002)

<a id="ref-8"></a>[8] Kim, S. Y., Park, Y. J., Yu, J. K., Kim, Y. S., & Han, K. (2012). Prevalence and characteristics of NDM-1-producing Enterobacteriaceae in a tertiary care hospital in Korea. *Annals of Laboratory Medicine*, 32(6), 415-419. [https://doi.org/10.3343/alm.2012.32.6.415](https://doi.org/10.3343/alm.2012.32.6.415)

<a id="ref-9"></a>[9] Nordmann, P., Poirel, L., & Dortet, L. (2012). Rapid detection of carbapenemase-producing Enterobacteriaceae. *Emerging Infectious Diseases*, 18(9), 1503-1507. [https://doi.org/10.3201/eid1809.120355](https://doi.org/10.3201/eid1809.120355)

<a id="ref-10"></a>[10] Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., ... & Woodford, N. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *The Lancet Infectious Diseases*, 10(9), 597-602. [https://doi.org/10.1016/S1473-3099(10)70143-2](https://doi.org/10.1016/S1473-3099(10)70143-2)

<a id="ref-11"></a>[11] Ito, A., Kohira, N., Bouchillon, S. K., West, J., Rittenhouse, S., Sader, H. S., ... & Tsuji, M. (2016). In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. *Journal of Antimicrobial Chemotherapy*, 71(3), 670-677. [https://doi.org/10.1093/jac/dkv402](https://doi.org/10.1093/jac/dkv402)

<a id="ref-12"></a>[12] Hamrick, J. C., Docquier, J. D., Uehara, T., Myers, C. L., Six, D. A., Davies, C. L., ... & Pevear, D. C. (2020). VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, 64(3), e01963-19. [https://doi.org/10.1128/AAC.01963-19](https://doi.org/10.1128/AAC.01963-19)

<a id="ref-13"></a>[13] Citorik, R. J., Mimee, M., & Lu, T. K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nature Biotechnology*, 32(11), 1141-1145. [https://doi.org/10.1038/nbt.3011](https://doi.org/10.1038/nbt.3011)